Clinical trials: Leukocytes
Invasive Fungal Infections, Neutropenic Fever
Human Bioequivalence Study of Amphotericin B Liposome for Injection
Single-center, randomized, open-label, single-dose, two-treatment, two-period, two-sequence crossover design to evaluate the human bioequivalence of two Amphotericin B Liposome for Injection formulations
- Conditions
- Invasive Fungal Infections, Neutropenic Fever, Visceral Leishmaniasis
- Trial name
- NCT06977490
- Testing
- Amphotericin B Liposome for Injection (strength: 50 mg, Sichuan Huiyu Pharmaceutical Co., Ltd.), Amphotericin B Liposome for Injection (trade name: Ambisome®, strength: 50 mg, MAH: Gilead Sciences)
- Where
- China
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Sichuan Huiyu Pharmaceutical Co., Ltd
Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)
The primary purpose of this study was to assess the tolerability of oral asciminib (80 mg QD) in comparison with that of the second generation (2G) Tyrosine Kinase Inhibitor (TKI) nilotinib (300 mg BID), in adult patients with…
- Trial name
- ASC4START (NCT05456191)
- Testing
- Asciminib, Nilotinib
- Where
- 119 sites in United States, Argentina and 22 more
- Volunteers
- 568 people
- Sponsor
- Novartis Pharmaceuticals
Neutropenia (Low White Blood Cell Count)
A Study to Compare the Pharmacokinetics, Pharmacodynamics, Immunogenicity, Safety and Tolerability of Filgrastim Biosimilar and Neupogen Reference Product in Healthy Volunteers
The goal of this clinical trial is to assess the pharmacokinetic similarity of Biofilgragen, a filgrastim biosimilar, compared with EU-authorized Neupogen after single subcutaneous doses in healthy adult volunteers.
- Trial name
- FIL-BIO-IMG (NCT07877467)
- Testing
- Biofilgragen, Neupogen (filgrastim)
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- BioGeneric Pharma
Bullous Pemphigoid
A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid.
The purpose of this study is to investigate the use of benralizumab is effective in the treatment of patients symptomatic Bullous Pemphigoid (BP).
- Trial name
- FJORD (NCT04612790)
- Testing
- Benralizumab
- Where
- 39 sites in United States, Australia and 9 more
- Volunteers
- 67 people
- Sponsor
- AstraZeneca
Asthma
Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics
The purpose of the study is to evaluate effect of benralizumab on structural and lung function changes in severe eosinophilic asthmatics.
- Trial name
- CHINOOK (NCT03953300)
- Testing
- Benralizumab
- Where
- 35 sites in United States, Canada and 3 more
- Volunteers
- 75 people
- Sponsor
- AstraZeneca
Neutropenia (Low White Blood Cell Count)
A Research Study To Test How Multiple Doses Of Filgrastim Hospira Works In The Body Of Healthy Study Subjects When Given by Subcutaneous Injection (SC) (Shot) Compared To An Already U.S.-Approved Drug Neupogen® (Amgen)
This is a study comparing two study drugs, Filgrastim Hospira and Neupogen®. Neupogen® is approved by the US Food and Drug Administration (FDA) to treat low numbers of specific kinds of white blood cells (WBC) known as…
- Trial name
- NCT02766634
- Testing
- Filgrastim Hospira (US), U.S.-approved Neupogen®
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Pfizer
Eosinophilic Duodenitis, Eosinophilic Gastroenteritis
A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis
This is a Phase 3, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of lirentelimab (AK002) given monthly for 6 doses in adult patients with active eosinophilic duodenitis.
- Trial name
- EoDyssey (NCT04856891)
- Testing
- AK002
- Where
- 39 sites in United States
- Volunteers
- 94 people
- Sponsor
- Allakos Inc.
Advanced Solid Tumor
A Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of ES009 administered intravenously to subjects with advanced solid tumors.
- Trial name
- NCT06007482
- Testing
- ES009
- Where
- 4 sites in Australia
- Volunteers
- 12 people
- Sponsor
- Elpiscience Biopharma Australia Pty. Ltd.
Chemotherapy-Induced Neutropenia
Study to Evaluate the Safety, Tolerability and PK of EC-18 After Oral Administration in Healthy Volunteers
This study is a Dose block-randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Escalation, Phase I clinical trial to assess the safety, tolerability and pharmacokinetics of single-dose and…
- Trial name
- NCT02532712
- Testing
- EC-18
- Where
- South Korea
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Enzychem Lifesciences Corporation
Healthy
Feasibility Study of Mirasol-Treated Whole Blood Red Cell Recovery and Survival
Feasibility trial to evaluate recovery and survival of red blood cells (RBCs) from Mirasol-treated whole blood
- Trial name
- IMPROVE (NCT00742001)
- Testing
- Mirasol System for Whole Blood.
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Terumo BCTbio
Chemotherapy-induced Neutropenia, Cancer, Breast
Fusion Protein rHSA/GCSFclinical Study on Breast Cancer Patients
The purpose of this study is to evaluate the tolerance and safety of the rHSA/GCSF in breast cancer patients with different doses and multiple injections.
- Trial name
- NCT03246009
- Testing
- rHSA/GCSF
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Tianjin SinoBiotech Ltd.
Eosinophilic Esophagitis
Study of Dupilumab in Adult Participants With Active Eosinophilic Esophagitis (EoE)
The primary objective of the study is to assess the clinical efficacy of repeat subcutaneous (SC) doses of dupilumab, compared with placebo, to relieve symptoms in adult participants with active, moderate to severe Eosinophilic…
- Trial name
- NCT02379052
- Testing
- Dupilumab
- Where
- 14 sites in United States
- Volunteers
- 47 people
- Sponsor
- Regeneron Pharmaceuticals
Hypereosinophilic Syndrome
This Record Contains Information About the Mepolizumab Compassionate Use (CU) Product Activities: 104317: CU and Long-Term Access Study of Mepolizumab in HES. 201956:A Long-term Access Programme for Subjects With Severe Asthma 112562: Expanded Access for Patients With Hypereosinophilic
104317: The market authorisation application for mepolizumab for the indication of hypereosinophilic syndrome (HES) was filed in 2008, but later the file was withdrawn due to outstanding questions from regulator's raised from the…
- Trial name
- NCT00244686
- Testing
- Mepolizumab
- Sponsor
- GlaxoSmithKline
Eosinophilic Esophagitis (EoE)
OBS in Adolescent and Adults With EOE: A Phase II, Randomized, Double-Blind, Placebo Controlled, Study With an Open Label Extension
This is a clinical trial to test an experimental drug for the treatment of Eosinophilic Esophagitis (EoE)
- Trial name
- NCT01642212
- Testing
- Oral Budesonide Suspension (MB-9)
- Where
- 23 sites in United States
- Volunteers
- 93 people
- Sponsor
- Shire
Neoplasms, Neutropenia
PC001- A Study to Evaluate the Usability of PointCheck
This a study about the usability of PointCheck a novel non-invasive technology for monitoring chemotherapy-induced neutropenia. The study will include patients with cancer visiting the outpatient hematology clinic for their…
- Trial name
- NCT04448301
- Testing
- PointCheck
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- Leuko Labs, Inc.
Leukemia, Myelocytic, Acute, Myelodysplastic Syndromes
Prophylaxis Trial of Posaconazole Versus Standard Azole Therapy for Neutropenic Patients (Study P01899)
This trial is in high risk patients to determine the safety and efficacy of posaconazole vs. fluconazole in the prophylaxis against development of invasive fungal infections.
- Conditions
- Leukemia, Myelocytic, Acute, Myelodysplastic Syndromes, Neutropenia
- Trial name
- NCT00044486
- Testing
- Posaconazole oral suspension
- Volunteers
- 602 people
- Sponsor
- Merck Sharp & Dohme LLC
Acute Coronary Syndrome, Angina Pectoris
Diagnostic Performance of Artificial Intelligence Algorithms in Prediction of Acute Coronary Syndrome Based on White Blood Cell Properties
The goal of this observational study is to evaluate whether artificial intelligence (AI) algorithms can predict or exclude acute coronary syndrome (ACS) in adults using data generated by routine hematology testing.
- Conditions
- Acute Coronary Syndrome, Angina Pectoris, NSTEMI - Non-ST Segment Elevation MI, STEMI - ST Elevation Myocardial Infarction
- Trial name
- NCT06384846
- Where
- Austria
- Volunteers
- 3,350 people, healthy volunteers welcome
- Sponsor
- RobotDreams GmbH
Breast Cancer
A Study to Evaluate the Efficacy, Safety and Immunogenicity of Leucostim® Versus Neupogen® in Breast Cancer Patients
A study to compare the efficacy, safety and immunogenicity of Leucostim® to those of Neupogen® in patients with breast cancer intended to be treated with TAC regimen as a myelosuppressive chemotherapy.
- Trial name
- NCT03343145
- Testing
- Leucostim 5µg/kg/day, Neupogen 5µg/kg/day
- Where
- Indonesia
- Volunteers
- 143 people
- Sponsor
- Dong-A ST Co., Ltd.
MPN (Myeloproliferative Neoplasms)
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
The purpose of this study is to evaluate the efficacy and safety of pemigatinib (INCB054828) in subjects with myeloid/lymphoid neoplasms with fibroblast growth factor receptor (FGFR) 1 rearrangement.
- Trial name
- NCT03011372
- Testing
- Pemigatinib
- Where
- 33 sites in United States, Austria and 9 more
- Volunteers
- 47 people
- Sponsor
- Incyte Corporation
HIV Infections
Double-Blind, Randomized, Placebo-Controlled Study of Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived) in ARC Patients
To conduct a parallel-group, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of an orally administered low dose interferon alfa-n3 as an immunomodulator in the treatment of mild to moderate…
- Trial name
- NCT00002012
- Testing
- Interferon alfa-n3
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Interferon Sciences